|
[1] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
|
|
[2] ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and meta-analysis[J]. Hepatology, 2019,70(4):1119-1133.
|
|
[3] ARAB JP, KARPEN SJ, DAWSON PA, et al. Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J]. Hepatology, 2017, 65(1):350-362.
|
|
[4] FORMAN BM, GOODE E, CHEN J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites[J].Cell, 1995, 81(5):687-693.
|
|
[5] CAVE MC, CLAIR HB, HARDESTY JE, et al. Nuclear receptors and nonalcoholic fatty liver disease[J]. Biochim Biophys Acta, 2016, 1859(9):1083-1099.
|
|
[6] NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT):A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385(9972):956-965.
|
|
[7] RATZIU V, SANYAL AJ, LOOMBA R, et al. REGENERATE:Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis[J]. Contemp Clin Trials,2019, 84:105803.
|
|
[8] FANG S, SUH JM, REILLY SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J]. Nat Med, 2015, 21(2):159-165.
|
|
[9] JIANG C, XIE C, LI F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J]. J Clin Invest, 2015, 125(1):386-402.
|
|
[10] LI T, CHIANG JY. Bile acid signaling in metabolic disease and drug therapy[J]. Pharmacol Rev, 2014, 66(4):948-983.
|
|
[11] MATSUBARA T, LI F, GONZALEZ FJ. FXR signaling in the enterohepatic system[J]. Mol Cell Endocrinol, 2013, 368(1-2):17-29.
|
|
[12] GOODWIN B, JONES SA, PRICE RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis[J]. Mol Cel, 2000, 6(3):517-526.
|
|
[13] TANAKA N, AOYAMA T, KIMURA S, et al. Targeting nuclear receptors for the treatment of fatty liver disease[J]. Pharmacol Ther, 2017, 179:142-157.
|
|
[14] GONZALEZ FJ, JIANG C, XIE C, et al. Intestinal farnesoid X receptor signaling modulates metabolic disease[J]. Dig Dis,2017, 35(3):178-184.
|
|
[15] SAYIN SI, WAHLSTRÖM A, FELIN J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist[J]. Cell Metab, 2013, 17(2):225-235.
|
|
[16] TURNBAUGH PJ, LEY RE, MAHOWALD MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest[J]. Nature, 2006, 444(7122):1027-1031.
|
|
[17] PAGADALA M, KASUMOV T, MCCULLOUGH AJ, et al. Role of ceramides in nonalcoholic fatty liver disease[J]. Trends Endocrinol Metab, 2012, 23(8):365-371.
|
|
[18] SUN R, YANG N, KONG B, et al. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway[J]. Mol Pharmacol, 2017, 91(2):110-122.
|
|
[19] TEMEL RE, BROWN JM. A new model of reverse cholesterol transport:EnTICEing strategies to stimulate intestinal cholesterol excretion[J]. Trends Pharmacol Sci, 2015, 36(7):440-451.
|
|
[20] de BOER JF, SCHONEWILLE M, BOESJES M, et al. Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice[J]. Gastroenterology, 2017, 152(5):1126-1138. e6.
|
|
[21] KIM YC, BYUN S, SEOK S, et al. Small heterodimer partner and fibroblast growth factor 19 inhibit expression of NPC1L1 in mouse intestine and cholesterol absorption[J]. Gastroenterology, 2019, 156(4):1052-1065.
|
|
[22] SUN L, PANG Y, WANG X, et al. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters[J].Acta Pharm Sin B, 2019, 9(4):702-710.
|
|
[23] JIANG C, XIE C, LV Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction[J]. Nat Commun, 2015, 6:10166.
|
|
[24] LI F, JIANG C, KRAUSZ KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity[J]. Nat Commun, 2013, 4:2384.
|
|
[25] van DIJK TH, GREFHORST A, OOSTERVEER MH, et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/-mice[J]. J Biol Chem, 2009, 284(16):10315-10323.
|
|
[26] PATHAK P, LIU H, BOEHME S, et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism[J]. J Biol Chem,2017, 292(26):11055-11069.
|
|
[27] TRABELSI MS, DAOUDI M, PRAWITT J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells[J]. Nat Commun, 2015, 6:7629.
|
|
[28] FANG Q, LI H, SONG Q, et al. Serum fibroblast growth factor19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels[J]. Diabetes Care, 2013, 36(9):2810-2814.
|
|
[29] KIR S, BEDDOW SA, SAMUEL VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis[J]. Science, 2011, 331(6024):1621-1624.
|
|
[30] LAN T, MORGAN DA, RAHMOUNI K, et al. FGF19, FGF21,and an FGFR1/β-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia[J]. Cell Metab, 2017, 26(5):709-718. e3.
|
|
[31] PATHAK P, XIE C, NICHOLS RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism[J].Hepatology, 2018, 68(4):1574-1588.
|
|
[32] XIE C, JIANG C, SHI J, et al. An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice[J]. Diabetes, 2017, 66(3):613-626.
|
|
[33] DEGIROLAMO C, MODICA S, VACCA M, et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptornull mice by intestinal-specific farnesoid X receptor reactivation[J]. Hepatology, 2015, 61(1):161-170.
|
|
[34] ARAGONÈS G, COLOM-PELLICER M, AGUILAR C, et al.Circulating microbiota-derived metabolites:A"liquid biopsy?[J]. Int J Obes(Lond), 2019.[Online ahead of print]
|
|
[35] ALISI A, CECCARELLI S, PANERA N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease[J]. PLoS One,2013, 8(6):e67160.
|
|
[36] RINELLA ME, TROTTER JF, ABDELMALEK MF, et al. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2019, 70(4):735-744.
|
|
[37] LUO J, KO B, ELLIOTT M, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases[J]. Sci Transl Med,2014, 6(247):247ra100.
|
|
[38] ZHOU M, LEARNED RM, ROSSI SJ, et al. Engineered FGF19eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice[J]. Hepatol Commun,2017, 1(10):1024-1042.
|
|
[39] WANG H, ZHAO Z, ZHOU J, et al. A novel intestinal-restricted FXR agonist[J]. Bioorg Med Chem Lett, 2017, 27(15):3386-3390.
|
|
[40] SUN L, XIE C, WANG G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin[J]. Nat Med,2018, 24(12):1919-1929.
|
DownLoad: